Quantbot Technologies LP Takes $575,000 Position in Nutex Health Inc. $NUTX

Quantbot Technologies LP acquired a new position in Nutex Health Inc. (NASDAQ:NUTX) during the third quarter, HoldingsChannel.com reports. The fund acquired 5,568 shares of the company’s stock, valued at approximately $575,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. BNP Paribas Financial Markets boosted its stake in shares of Nutex Health by 966.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock worth $40,000 after buying an additional 290 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in Nutex Health during the third quarter valued at approximately $30,000. Ameritas Investment Partners Inc. bought a new position in Nutex Health in the second quarter valued at approximately $44,000. KLP Kapitalforvaltning AS increased its position in shares of Nutex Health by 66.7% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 1,500 shares of the company’s stock worth $155,000 after purchasing an additional 600 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Nutex Health in the 2nd quarter valued at approximately $97,000. 5.32% of the stock is currently owned by institutional investors and hedge funds.

Nutex Health Price Performance

Shares of NASDAQ NUTX opened at $90.28 on Monday. The business’s 50 day moving average is $136.67 and its 200-day moving average is $124.93. The firm has a market cap of $629.25 million, a P/E ratio of 10.05 and a beta of 0.04. Nutex Health Inc. has a 1-year low of $40.67 and a 1-year high of $193.07. The company has a current ratio of 3.41, a quick ratio of 3.39 and a debt-to-equity ratio of 0.70.

Nutex Health (NASDAQ:NUTX) last posted its quarterly earnings data on Thursday, March 5th. The company reported $1.61 earnings per share for the quarter, missing the consensus estimate of $5.56 by ($3.95). The firm had revenue of $151.68 million for the quarter, compared to the consensus estimate of $258.82 million. Nutex Health had a return on equity of 17.67% and a net margin of 7.34%.

Key Stories Impacting Nutex Health

Here are the key news stories impacting Nutex Health this week:

• Positive Sentiment: Nutex reported strong full‑year 2025 results (revenue +82% y/y to $875.3M; net income and EPS up; adjusted EBITDA +152.6%) and announced a second stock repurchase program — news that can support the stock over time by reducing share count and signaling management confidence. NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM
• Positive Sentiment: Analyst/coverage pieces are discussing valuation upside given earnings growth and the buyback, which may attract long‑term investors focused on fundamentals. Assessing Nutex Health (NUTX) Valuation After Earnings Growth And New Share Buyback Program
• Neutral Sentiment: Corporate press releases and financial filings provide the detailed numbers and management commentary — useful for investors doing due diligence but unlikely to move the market on their own. Company Press Release / Financial Report
• Negative Sentiment: Nutex’s most recent quarterly report missed expectations sharply (EPS $1.61 vs. $5.56 est.; revenue $151.7M vs. $258.8M), a short‑term catalyst for selling as it signals volatility in recent revenue drivers. MarketBeat: Earnings Summary
• Negative Sentiment: Multiple law firms (Block & Leviton, Kuehn Law and others) have launched investigations or encouraged shareholders to contact them over potential securities fraud and fiduciary‑duty claims tied to disclosure of revenue recognition and internal controls — a major overhang that raises litigation risk, potential settlements, and reputational damage. Block & Leviton Investigation Notice
• Negative Sentiment: Additional press items detail similar shareholder litigation allegations about HaloMD-related revenue recognition, internal control weaknesses, and stock‑based compensation treatment — issues that could lead to restatements or future liabilities. Kuehn Law Notice
• Negative Sentiment: Local/regional reporting highlights investor outreach from law firms, amplifying negative headlines and short‑term selling pressure. GazetteXtra: Investor Advisory

Wall Street Analyst Weigh In

NUTX has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Nutex Health from a “strong-buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nutex Health in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.50.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.